Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: July 8, 2025
Event: Unregistered sales of equity securities and acquisition of a joint venture interest.
Key Financial Metrics and Transaction Details
This filing reports a specific transaction rather than periodic financial results. Key metrics related to the transaction include:
- Transaction Type: Acquisition of 50% of the membership interests of RE Ventures I, LLC ("ENPP1 JV") from Rallybio Corporation.
- Ownership Change: Recursion previously held 50% of ENPP1 JV; post-acquisition, ENPP1 JV is an indirect wholly-owned subsidiary.
- Initial Equity Consideration: 1,457,952 shares of Class A Common Stock issued to the Seller.
- Valuation Basis: Shares calculated using a volume-weighted average price of $5.1442 (based on the seven trading days ending July 7, 2025), representing a value of $7,500,000.
- Contingent Equity Consideration: Up to $12,500,000 in value payable in shares upon satisfaction of specific milestones for the compound developed by ENPP1 JV.
- Equity Cap: Total shares issued under the agreement are capped at 19.9% of the Company's outstanding Class A and Class B common stock (whichever is less at the time of issuance). Excess consideration will be paid in cash.
- Cash Consideration: Additional cash payments were made as partial consideration, with further contingent cash payments possible based on proceeds from share sales and future milestones.
Note: The filing does not provide data on overall company revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes Versus Prior Period
The primary material change is the consolidation of the ENPP1 JV. Prior to July 8, 2025, Recursion held a 50% interest in the joint venture. Following the acquisition, the joint venture is now fully consolidated as a wholly-owned subsidiary. This transaction alters the Company's capital structure through the issuance of new shares and cash outflows.
Guidance, Outlook, Risks, and Unusual Items
- Management Commentary: The Company issued a press release (Exhibit 99.1) announcing the acquisition, which is incorporated by reference.
- Registration Rights: The Company agreed to file a registration statement (or utilize an automatic shelf registration) to allow the Seller to resell the issued shares. The Company will maintain the effectiveness of this registration until all shares are sold or eligible for unrestricted sale under Rule 144.
- Risks and Contingencies:
- Forward-Looking Statements: The report contains forward-looking statements regarding obligations under the Purchase Agreement, subject to risks and uncertainties.
- Regulatory Risk: The shares were issued under Section 4(a)(2) of the Securities Act and have not been registered; they cannot be offered or sold in the U.S. absent registration or an exemption.
- Milestone Risk: Future equity and cash payments are contingent on the success of the compound developed by the ENPP1 JV.
Important Facts for Investor Verification
- Verify the exact number of shares outstanding as of July 7, 2025, to calculate the precise dilution impact of the 19.9% share cap.
- Review the specific milestones defined in the Purchase Agreement that trigger the $12,500,000 contingent equity payment.
- Confirm the amount of additional cash consideration paid at closing, as the filing states "additional cash consideration in the amounts set forth in the Purchase Agreement" without specifying the figure in the text.
- Monitor the filing of the registration statement for the resale of the 1,457,952 Initial Shares.
- Assess the financial impact of consolidating the ENPP1 JV on future quarterly and annual financial statements.